ZA978133B - Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride - Google Patents
Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochlorideInfo
- Publication number
- ZA978133B ZA978133B ZA978133A ZA978133A ZA978133B ZA 978133 B ZA978133 B ZA 978133B ZA 978133 A ZA978133 A ZA 978133A ZA 978133 A ZA978133 A ZA 978133A ZA 978133 B ZA978133 B ZA 978133B
- Authority
- ZA
- South Africa
- Prior art keywords
- alpha
- methoxyimino
- azabicyclo
- oct
- dosage form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9619074.9A GB9619074D0 (en) | 1996-09-12 | 1996-09-12 | Composition |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA978133B true ZA978133B (en) | 1999-04-12 |
Family
ID=10799833
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA978133A ZA978133B (en) | 1996-09-12 | 1997-09-10 | Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0929301A2 (fr) |
JP (1) | JP2001500150A (fr) |
KR (1) | KR20000036039A (fr) |
CN (2) | CN1235544A (fr) |
AR (1) | AR008176A1 (fr) |
AU (1) | AU724086B2 (fr) |
BR (1) | BR9711734A (fr) |
CA (1) | CA2265661A1 (fr) |
CO (1) | CO5031291A1 (fr) |
CZ (1) | CZ83299A3 (fr) |
GB (1) | GB9619074D0 (fr) |
HU (1) | HUP9904401A3 (fr) |
ID (1) | ID19589A (fr) |
IL (1) | IL128781A0 (fr) |
MA (1) | MA24359A1 (fr) |
NO (1) | NO991194D0 (fr) |
NZ (1) | NZ334268A (fr) |
PE (1) | PE2499A1 (fr) |
PL (1) | PL332074A1 (fr) |
TR (1) | TR199900505T2 (fr) |
WO (1) | WO1998010762A2 (fr) |
ZA (1) | ZA978133B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2775597B1 (fr) * | 1998-03-04 | 2001-04-20 | Gattefosse Ets Sa | Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication |
AU748396C (en) * | 1998-03-11 | 2003-01-23 | Smithkline Beecham Corporation | Composition |
DE19918325A1 (de) * | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
FR2796840B1 (fr) * | 1999-07-26 | 2003-06-20 | Ethypharm Lab Prod Ethiques | Comprimes faiblement doses et procede de preparation |
US6733781B2 (en) * | 2000-12-06 | 2004-05-11 | Wyeth | Fast dissolving tablet |
PA8578501A1 (es) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
CN100563648C (zh) * | 2003-04-25 | 2009-12-02 | 田边三菱制药株式会社 | 包含亚烷基二氧苯衍生物的口服组合物 |
EP1628642B2 (fr) * | 2003-05-14 | 2013-01-23 | Aptalis Pharma Limited | Composition pour liberation controlee de medicament resistant au stress mecanique in vivo |
US20050142191A1 (en) * | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
JP2005272347A (ja) * | 2004-03-24 | 2005-10-06 | Ohara Yakuhin Kogyo Kk | 固形製剤の製造方法 |
EA201001083A1 (ru) | 2004-08-13 | 2011-08-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Композиция таблетки пролонгированного высвобождения, содержащая прамипексол или его фармацевтически приемлемую соль, способ ее изготовления и ее применение |
SG164375A1 (en) * | 2004-08-13 | 2010-09-29 | Boehringer Ingelheim Int | Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
EP1970056A1 (fr) * | 2007-03-15 | 2008-09-17 | Polichem S.A. | Formules de dosages à libération retardée/pulsatile spécifique au temps |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG48315A1 (en) * | 1989-04-13 | 1998-04-17 | Beecham Group Plc | Novel compounds |
GB9409718D0 (en) * | 1994-05-14 | 1994-07-06 | Smithkline Beecham Plc | Novel compounds |
GB9421472D0 (en) * | 1994-10-25 | 1994-12-07 | Smithkline Beecham Plc | Novel methods |
AR004178A1 (es) * | 1995-07-29 | 1998-11-04 | Smithkline Beecham Plc | Procedimiento para la formulacion de un farmaco, una composicion farmaceutica obtenible mediante este procedimiento y el uso de la misma. |
-
1996
- 1996-09-12 GB GBGB9619074.9A patent/GB9619074D0/en active Pending
-
1997
- 1997-09-08 WO PCT/GB1997/002418 patent/WO1998010762A2/fr not_active Application Discontinuation
- 1997-09-08 TR TR1999/00505T patent/TR199900505T2/xx unknown
- 1997-09-08 CA CA002265661A patent/CA2265661A1/fr not_active Abandoned
- 1997-09-08 PL PL97332074A patent/PL332074A1/xx unknown
- 1997-09-08 JP JP10513352A patent/JP2001500150A/ja active Pending
- 1997-09-08 AU AU41288/97A patent/AU724086B2/en not_active Ceased
- 1997-09-08 CN CN97199411A patent/CN1235544A/zh active Pending
- 1997-09-08 BR BR9711734A patent/BR9711734A/pt unknown
- 1997-09-08 IL IL12878197A patent/IL128781A0/xx unknown
- 1997-09-08 KR KR1019997002030A patent/KR20000036039A/ko not_active Application Discontinuation
- 1997-09-08 HU HU9904401A patent/HUP9904401A3/hu unknown
- 1997-09-08 EP EP97939064A patent/EP0929301A2/fr not_active Withdrawn
- 1997-09-08 NZ NZ334268A patent/NZ334268A/xx unknown
- 1997-09-08 CZ CZ99832A patent/CZ83299A3/cs unknown
- 1997-09-09 CO CO97052280A patent/CO5031291A1/es unknown
- 1997-09-10 ZA ZA978133A patent/ZA978133B/xx unknown
- 1997-09-10 AR ARP970104130A patent/AR008176A1/es not_active Application Discontinuation
- 1997-09-10 ID IDP973137A patent/ID19589A/id unknown
- 1997-09-10 PE PE1997000805A patent/PE2499A1/es not_active Application Discontinuation
- 1997-09-10 MA MA24792A patent/MA24359A1/fr unknown
-
1999
- 1999-03-11 NO NO991194A patent/NO991194D0/no unknown
-
2003
- 2003-01-23 CN CN03102977A patent/CN1446535A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
PE2499A1 (es) | 1999-03-24 |
AU4128897A (en) | 1998-04-02 |
CO5031291A1 (es) | 2001-04-27 |
EP0929301A2 (fr) | 1999-07-21 |
CN1446535A (zh) | 2003-10-08 |
AR008176A1 (es) | 1999-12-09 |
WO1998010762A2 (fr) | 1998-03-19 |
JP2001500150A (ja) | 2001-01-09 |
CZ83299A3 (cs) | 1999-08-11 |
HUP9904401A3 (en) | 2001-03-28 |
TR199900505T2 (fr) | 1999-06-21 |
PL332074A1 (en) | 1999-08-30 |
BR9711734A (pt) | 1999-08-24 |
GB9619074D0 (en) | 1996-10-23 |
NZ334268A (en) | 2000-10-27 |
AU724086B2 (en) | 2000-09-14 |
KR20000036039A (ko) | 2000-06-26 |
NO991194L (no) | 1999-03-11 |
NO991194D0 (no) | 1999-03-11 |
WO1998010762A3 (fr) | 1998-06-04 |
HUP9904401A2 (hu) | 2000-06-28 |
IL128781A0 (en) | 2000-01-31 |
ID19589A (id) | 1998-07-23 |
CN1235544A (zh) | 1999-11-17 |
CA2265661A1 (fr) | 1998-03-19 |
MA24359A1 (fr) | 1998-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EG20650A (en) | Opioid formulations having extended controlled release | |
EG24291A (en) | Novel form of s-omeprazole | |
PL331862A1 (en) | Tablet featurated by controllable release of alphusozine hydrochloride contained therein | |
PL352100A1 (en) | Antagonists of the beta 2 adrenoreceptor | |
HUP0003217A3 (en) | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and pharmaceutical compositions containing them | |
ZA9880B (en) | Table for the controlled release of active agents | |
PL338563A1 (en) | Substituted derivatives of 1,2,3,4-tetrahydronaphtalene | |
EP1017980A4 (fr) | Procede d'identification de composes pharmaceutiquement actifs | |
ZA978133B (en) | Controlled release dosage form of (R-(z))-alpha-(methoxyimino)-alpha-(C1-azabicyclo (2.2.2) Oct-3-yl) acetonitrile monohydrochloride | |
HUP0101043A3 (en) | Controlled release oral dosage form containing [r-(z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2]oct-3-yl]acetonitrile monohydrochlorid and process for its preparation | |
GB0014805D0 (en) | Glassbreaker (2) | |
HUP0003737A3 (en) | New process for the preparation of omeprazole | |
IL131392A0 (en) | Process for the preparation of substituted thiazolidinedione | |
GB2357758B (en) | Process for the preparation of 1,1-cyclopropanedicarboxylic diesters | |
ZA988397B (en) | Process for the preparation of substituted 5,6-dihydro-2H-pyran-2-ones | |
TW385094U (en) | Improvement of the video distributor | |
ZA9811285B (en) | New pharmaceutically active compounds | |
GB9602173D0 (en) | Pharmaceutically active compounds | |
GB9610474D0 (en) | Pharmaceutically active compounds | |
GB9610892D0 (en) | Pharmaceutically active compounds | |
GB9602668D0 (en) | Pharmaceutically active compounds | |
GB9614386D0 (en) | Pharmaceutically active compounds | |
GB9616477D0 (en) | Pharmaceutically active compounds | |
GB9610499D0 (en) | Pharmaceutically active compounds | |
GB9602667D0 (en) | Pharmaceutically active compounds |